Nuvation Bio Inc reports results for the quarter ended June 30 - Earnings Summary

Nuvation Bio

07/08/2025 18:28

Nuvation Bio Inc NUVB.N reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -15 cents.  The mean expectation of seven analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -19 cents to -15 cents per share.

Revenue rose 236.8% to $4.83 million from a year ago; analysts expected $357.14 thousand.

Nuvation Bio Inc's reported EPS for the quarter was a loss of 17 cents​.

The company reported a quarterly loss of $59.01 million.

Nuvation Bio Inc shares had risen by 20.5% this quarter and lost 11.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Nuvation Bio Inc is $6.00, about 60.8% above its last closing price of $2.35

This summary was machine generated from LSEG data August 7 at 05:27 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.17
-0.17
Met
Mar. 31 2025
-0.16
-0.16
Met
Dec. 31 2024
-0.14
-0.15
Missed
Sep. 30 2024
-0.13
-0.15
Missed